EUVIMEDSkopri EUVIMED
Open access · CC BY 4.0

Engineering Murine Cross‐Reactivity Into an Affibody to Human Death Receptor 5

Tse-Han Kuo, Nagamani Vunnam, Jonathan N Sachs, Benjamin J Hackel

Biotechnology and Bioengineering · 2026

DOI: 10.1002/bit.70216 ↗

At a glance

Journal article in Biotechnology and Bioengineering, 2026. Written by Tse-Han Kuo and 3 co-authors. Institution: Department of Chemical Engineering and Materials Science, University of Minnesota - Twin Cities, Minneapolis, Minnesota, USA. Major MEDLINE topics: Receptors, TNF-Related Apoptosis-Inducing Ligand, Protein Engineering, Recombinant Fusion Proteins. 50 references. The full text is freely available (open access, CC BY 4.0). Funded by: NIBIB NIH HHS, NIGMS NIH HHS, NIH HHS.

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

Interspecies cross‐reactive protein therapeutics that target conserved epitopes across species are critical for translational research. The present study showcases the engineering of an affibody molecule, originally discovered for binding to human death receptor 5 (hDR5) with 94 nM affinity, to simultaneously acquire cross‐reactivity to murine DR5 and enhance its binding affinity to human DR5. DR5 plays a pivotal role in metabolic dysfunction‐associated steatohepatitis (MASH) by mediating hepatocyte apoptosis and inflammation. Utilizing a rationally designed library guided by enrichment information and a helix‐walking mutagenesis strategy, combined with alternating binding selections between human and murine DR5, we evolved affibody variants exhibiting significantly improved binding to both receptors. Deep sequencing revealed amino acid preferences in the paratope, and the dominant variant, ABY DR5‐A , demonstrated over 1000‐fold and 16‐fold affinity improvements to murine and human DR5, respectively, with equilibrium dissociation constants of 15 and 5.8 nM. ABY DR5‐A exhibited nanomolar IC 50 values for antagonism of TRAIL‐induced DR5 signaling, measured via caspase 8 activation, in both murine and human cells, albeit with incomplete inhibition. This engineered affibody provides a promising candidate for therapeutic development targeting DR5‐mediated liver disease. Further functional characterization and pharmacokinetic optimization are required to advance these findings toward preclinical evaluation in murine MASH models and, ultimately, clinical applications.

Subjects

MeSH terms (MEDLINE)

Receptors, TNF-Related Apoptosis-Inducing LigandProtein EngineeringRecombinant Fusion ProteinsAnimalsHumansMiceCross ReactionsProtein Binding

Substances

Receptors, TNF-Related Apoptosis-Inducing LigandRecombinant Fusion ProteinsTNFRSF10B protein, human

Authors and institutions

  • Department of Chemical Engineering and Materials Science, University of Minnesota - Twin Cities, Minneapolis, Minnesota, USA.
  • Department of Biomedical Engineering, University of Minnesota - Twin Cities, Minneapolis, Minnesota, USA.

Funding

  • NIBIB NIH HHS
  • NIGMS NIH HHS
  • NIH HHS
  • National Institutes of Health

Cite

APA

Kuo, T. H., Vunnam, N., Sachs, J. N., & Hackel, B. J. (2026). Engineering Murine Cross‐Reactivity Into an Affibody to Human Death Receptor 5. Biotechnology and Bioengineering. https://doi.org/10.1002/bit.70216

Vancouver

Kuo TH, Vunnam N, Sachs JN, Hackel BJ. Engineering Murine Cross‐Reactivity Into an Affibody to Human Death Receptor 5. Biotechnology and Bioengineering. 2026. doi:10.1002/bit.70216

BibTeX
@article{Kuo2026,
  author = {Kuo, Tse-Han and Vunnam, Nagamani and Sachs, Jonathan N and Hackel, Benjamin J},
  title = {Engineering Murine Cross‐Reactivity Into an Affibody to Human Death Receptor 5},
  journal = {Biotechnology and Bioengineering},
  year = {2026},
  doi = {10.1002/bit.70216}
}
Start for free →